Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

6 Months Ended

Jan. 31, 2016

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2016	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	17,523			—			—			—		$	17,523
Product revenues		—		$	6,578			—			—			6,578
Royalty and license fee income		—			459			—			—			459
		17,523			7,037			—			—			24,560
Operating expenses:
Cost of clinical laboratory services		10,535			—			—			—			10,535
Cost of product revenues		—			3,206			—			—			3,206
Research and development		—			661		$	200			—			861
Selling, general and administrative		5,649			2,773			—		$	2,858			11,280
Provision for uncollectible accounts receivable		467			(8	)		—			—			459
Legal fee expense		57			5			—			2,349			2,411
Legal settlements, net		1,500			(13,150	)		—			—			(11,650	)
Total operating expenses		18,208			(6,513	)		200			5,207			17,102

Operating income (loss)		(685	)		13,550			(200	)		(5,207	)		7,458

Other income (expense)
Interest		(23	)		17			—			(36	)		(42	)
Other		(1	)		—			—			12			11
Foreign exchange loss		—			(388	)		—			—			(388	)
Income (loss) before income taxes	$	(709	)	$	13,179		$	(200	)	$	(5,231	)	$	7,039

Depreciation and amortization included above	$	411		$	524		$	—		$	17		$	952

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			—			—			—			—
Selling, general and administrative		9		$	5			—		$	94			108
Total	$	11		$	5		$	—		$	94		$	110

Capital expenditures	$	354		$	84		$	—		$	—		$	438

Three months ended January 31, 2015	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	14,725			—			—			—		$	14,725
Product revenues		—		$	7,723			—			—			7,723
Royalty and license fee income		—			644			—			—			644
		14,725			8,367			—			—			23,092
Operating expenses:
Cost of clinical laboratory services		9,246			—			—			—			9,246
Cost of product revenues		—			3,818			—			—			3,818
Research and development		—			635		$	199			—			834
Selling, general and administrative		5,089			2,704			—		$	1,877			9,670
Provision for uncollectible accounts receivable		658			(57	)		—			—			601
Legal fee expense		41			(53	)		—			2,816			2,804
Total operating expenses		15,034			7,047			199			4,693			26,973

Operating income (loss)		(309	)		1,320			(199	)		(4,693	)		(3,881	)

Other income (expense)
Interest		(12	)		5			—			(42	)		(49	)
Other		4			(29	)		—			8			(17	)
Foreign exchange loss		—			(259	)		—			—			(259	)
Income (loss) before income taxes	$	(317	)	$	1,037		$	(199	)	$	(4,727	)	$	(4,206	)

Depreciation and amortization included above	$	357		$	555		$	1		$	22		$	935

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—		$	1			—			—			1
Selling, general and administrative		12			3			—		$	87			102
Total	$	14		$	4		$	—		$	87		$	105

Capital expenditures	$	338		$	51		$	—		$	—		$	389

Six months ended January 31, 2016	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	34,613			—			—			—		$	34,613
Product revenues		—		$	14,265			—			—			14,265
Royalty and license fee income		—			859			—			—			859
		34,613			15,124			—			—			49,737
Operating expenses:
Cost of clinical laboratory services		20,867			—			—			—			20,867
Cost of product revenues		—			6,817			—			—			6,817
Research and development		—			1,328		$	400			—			1,728
Selling, general and administrative		10,935			5,832			—		$	4,738			21,505
Provision for uncollectible accounts receivable		1,175			(12	)		—			—			1,163
Legal fee expense		66			(17	)		—			3,963			4,012
Legal settlements, net		1,500			(19,950	)		—			—			(18,450	)
Total operating expenses		34,543			(6,002	)		400			8,701			37,642

Operating income (loss)		70			21,126			(400	)		(8,701	)		12,095

Other income (expense)
Interest		(42	)		31			—			(71	)		(82	)
Other		3			39			—			23			65
Foreign exchange loss		—			(518	)		—			—			(518	)
Income (loss) before income taxes	$	31		$	20,678		$	(400	)	$	(8,749	)	$	11,560

Depreciation and amortization included above	$	808		$	1,054		$	—		$	40		$	1,902

Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—			—			—			—			—
Selling, general and administrative		19		$	10			—		$	189			218
Total	$	22		$	10		$	—		$	189		$	221

Capital expenditures	$	791		$	152		$	—		$	—		$	943

Six months ended January 31, 2015	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	30,547			—			—			—		$	30,547
Product revenues		—		$	15,725			—			—			15,725
Royalty and license fee income		—			1,644			—			—			1,644
		30,547			17,369			—			—			47,916
Operating expenses:
Cost of clinical laboratory services		19,376			—			—			—			19,376
Cost of product revenues		—			7,513			—			—			7,513
Research and development		—			1,183		$	442			—			1,625
Selling, general and administrative		10,157			5,853			—		$	3,945			19,955
Provision for uncollectible accounts receivable		1,189			(47	)		—			—			1,142
Legal fee expense		131			(51	)		—			5,190			5,270
Total operating expenses		30,853			14,451			442			9,135			54,881

Operating income (loss)		(306	)		2,918			(442	)		(9,135	)		(6,965	)

Other income (expense)
Interest		(39	)		7			—			(86	)		(118	)
Other		6			(35	)		—			31			2
Foreign exchange gain		—			(731	)		—			—			(731	)
Income (loss) before income taxes	$	(339	)	$	2,159		$	(442	)	$	(9,190	)	$	(7,812	)

Depreciation and amortization included above	$	714		$	1,113		$	2		$	44		$	1,873

Share-based compensation included in above:
Cost of clinical laboratory services	$	3			—			—			—		$	3
Research and development		—		$	2			—			—			2
Selling, general and administrative		21			3			—		$	174			198
Total	$	24		$	5		$	—		$	174		$	203

Capital expenditures	$	589		$	64		$	—		$	—		$	653